A Phase 1/2 interventional study of Pandemic flu H5 HA mRNA SD2 vaccine and Placebo in Pandemic Influenza Immunization and Healthy Volunteers, sponsored by Sanofi. Active, not recruiting at 13 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-16.
Sponsored by Sanofi · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Influenza, Human by Sanofi — 4 open to participants now, 6 under way, 1 of them phase 3. Influenza, Human · Sanofi.
Among the 139 studies in Influenza, Human by Sanofi, this one is the 40th largest by enrollment of the 126 interventional ones that give a count, is one of 3 that started in 2025, is one of 13 in phase 1/2, and was the 135th registered.
2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.
Browse Influenza, Human studies →4 of the 139 studies in Influenza, Human by Sanofi are open now, in 3 countries. Recruiting first, the newest first:
Sanofi · Sites in Poland
Ages 60+ · Healthy volunteers
Sanofi · Sites in Korea, Republic of
Ages 65+ · Healthy volunteers
Sanofi · Sites in United States
Ages 18+ · Healthy volunteers
Sanofi · Sites in Korea, Republic of
Ages 65+ · Healthy volunteers
By country, each count listing its studies:
Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 47 · Phase 3 35 · Phase 4 33
First in 2003; this study’s year is marked. 3 started in 2025.
This study's enrollment of 720 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 305 across the 126 interventional studies, 1,001 across the 13 observational. Of the 133 that completed or were terminated, 73 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
2 of the studies in Influenza, Human by Sanofi that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06907511SanofiStudy to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older | 2026-12-01 |
| NCT07516418SanofiStudy of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age | 2027-04-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 139 studies in Influenza, Human by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this phase 1/2 study is to investigate the safety and immunogenicity of different doses (high, medium and low) of a second generation structurally designed (SD2) H5 messenger ribonucleic acid (mRNA) vaccine against pandemic H5 influenza virus (pandemic flu H5 hemagglutinin (HA) mRNA SD2) in healthy younger and older adults.
The study will aim to identify the appropriate dose for further clinical development of a potential pandemic response vaccine.
The study also includes an extension phase for one of the 3 dose levels of the pandemic flu H5 HA mRNA SD2 vaccine to collect additional safety and the immunogenicity data for this specific dose of the vaccine. During this Extension Phase, an additional 480 participants will be randomized according to a 1:1 ratio and stratified by age (≥ 18 to \< 65 years and ≥ 65 years) to receive either the low dose of the pandemic flu H5 HA mRNA DS2 vaccine (Group 1) or placebo (Group 4). This extension will enhance the safety database and improve precision of the immunogenicity results for the selected dose while preserving the original study design integrity.
The study duration per participant will be approximately 13 months. There will be two injections of placebo or pandemic flu H5 mRNA vaccine 21 days apart at high, medium and low doses.
Study visits/contact include: 7 study visits and 1 telephone call. Vaccination visits (including blood samples) will occur at Day 01 and Day 22. Short-term follow-up visits (including blood samples) will occur 8 and 21 days after each injection. Participants will be also followed up (including blood samples) at 3 and 6 months after 2nd injection, and at 12 months after 2nd injection for safety.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:
OR
Exclusion Criteria:
Note: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive two injections of low dose pandemic flu H5 HA mRNA SD2 vaccine Extension Phase: Additional participants will receive two injections 21 days apart of pandemic flu H5 HA mRNA SD2 vaccine at low dose
Biological: Pandemic flu H5 HA mRNA SD2 vaccine
Participants will receive two injections of medium dose pandemic flu H5 HA mRNA SD2 vaccine
Biological: Pandemic flu H5 HA mRNA SD2 vaccine
Participants will receive two injections of high dose pandemic flu H5 HA mRNA SD2 vaccine
Biological: Pandemic flu H5 HA mRNA SD2 vaccine
Participants will receive two injections of placebo Extension Phase: Additional participants will receive two injections 21 days apart of placebo
Other: Placebo
Pharmaceutical Form: Suspension in a vial Route of Administration: Intramuscular injection
Pharmaceutical Form: Liquid solution in a vial Route of Administration: Intramuscular injection
Presence of immediate adverse events (AEs)
Number of participants with immediate AEs
Time frame: Within 30 minutes after each/any injection
Presence of solicited injection site reactions
Number of participants with solicited injection site reactions
Time frame: Through 7 days after each/any injection
Presence of solicited systemic reactions
Number of participants with solicited systemic reactions
Time frame: Through 7 days after each/any injection
Presence of unsolicited AEs
Number of participants with unsolicited AEs
Time frame: Through 21 days after the first injection through 28 days after the second injection
Presence of medically attended adverse events (MAAEs)
Number of participants with MAAEs
Time frame: Through 180 days after the last injection
Presence of adverse events of special interest (AESIs)
Number of participants with AESIs
Time frame: Throughout the study, approximately 13 months
Presence of serious adverse events (SAEs)
Number of participants with SAEs
Time frame: Throughout the study, approximately 13 months
Presence of out-of-range biological test results (including shift from baseline values)
Number of participants with out-of-range biological test results
Time frame: Through a maximum of 8 days after each injection
Geometric mean titers (GMTs) of antibodies (Abs) against investigational pandemic flu H5 HA mRNA SD2 vaccine
Ab titer measured by hemagglutination inhibition (HAI) assay
Time frame: Day 01, Day 22, Day 43, Day 112 and Day 202
Individual HA titer ratio
Geometric mean ratio (GMR) HAI titers ratio
Time frame: Day22/Day01, Day43/Day01, Day112/Day01, and Day202/Day01
Seroconversion HAI Titer
Percentage of participants with seroconversion Seroconversion is defined by: HAI titer \< 10 \[1/dilution (dil)\] on Day 01 and post-injection titer ≥ 40 \[1/dil\] on Day 22 or Day 43; or defined as HAI titer ≥ 10 \[1/dil\] on D01 and a ≥ 4-fold increase in titer \[1/dil\]) on Day 22 or Day 43
Time frame: Day 01, Day 22 and Day 43
HAI titer ≥ 40 (1/dil)
Percentage of participants with HAI titer ≥ 40 (1/dil)
Time frame: Day 01, Day 22, Day 43, Day 112, and Day 202
Detectable HAI titer ≥ 10 (1/dil)
Percentage of participants with HAI titer ≥ 10 (1/dil)
Time frame: Day 01, Day 22, Day 43, Day 112, and Day 202
GMTs of Abs against investigational pandemic flu H5 HA mRNA SD2 vaccine
Ab titer measured by seroneutralization (SN) test
Time frame: Day 01, Day 22, Day 43, Day 112 and Day 202
Individual SN titer ratio
GMR SN titers ratio
Time frame: Day 22/Day 02, Day 43/Day 01, Day 112/Day 01 and Day 202/Day 01
SN titer ≥ 20 (1/dil)
Percentage of participants with SN titer ≥ 20 (1/dil)
Time frame: Day 01, Day 22, Day 43, Day 112 and Day 202
SN titer ≥ 40 (1/dil)
Percentage of participants with SN titer ≥ 40 (1/dil)
Time frame: Day 01, Day 22, Day 43, Day 112 and Day 202
SN titer ≥ 80 (1/dil)
Percentage of participants with SN titer ≥ 80 (1/dil)
Time frame: Day 01, Day 22, Day 43, Day 112 and Day 202
Detectable SN titer ≥ 10 (1/dil)
Percentage of participants with SN titer ≥ 10 (1/dil)
Time frame: Day 01, Day 22, Day 43, Day 112, and Day 202
2-fold and 4-fold rise in SN titer
Percentage of participants with fold increase in SN Ab titer \[post-vaccination / pre- vaccination\] ≥ 2 and ≥ 4 on D22 and D43
Time frame: Day 22 and Day 43
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org.
Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.
Of 41 industry-sponsored phase 1/2 interventional studies under Influenza, Human, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's planned 19 months is above that.
Counting every sponsor, half of 43 studies reached it within 12 months; a quarter within 7 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.